FAM20C

Across TCGA pan-cancer cohorts, FAM20C mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM20C data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM20C mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM20C expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where FAM20C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	47	view →
PDAC	DFS	Median	All	0.209	0.519	<.001	31	view →
GBM	DFS	Median	All	0.247	0.501	<.001	14	view →
LSCC	DFS	Tertile	II,III,IV	0.881	0.595	.007	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM20C–CCRCC (DFS)

Open the CCRCC breakdown →